
- Oncology NEWS International Vol 11 No 3
- Volume 11
- Issue 3
Dr. Klausner Co-Chairs Committee Preparing NAS Terrorism Report
WASHINGTON-A National Academy of Sciences (NAS) committee expects to issue a report in June on terrorism that will provide the federal government with a road map for the use of science and technology in all aspects of counterterrorism, Richard D. Klausner, MD, former National Cancer Institute (NCI) director, told ONI.
WASHINGTONA National Academy of Sciences (NAS) committee expects to issue a report in June on terrorism that will provide the federal government with a road map for the use of science and technology in all aspects of counterterrorism, Richard D. Klausner, MD, former National Cancer Institute (NCI) director, told ONI.
Dr. Klausner and Lewis M. Branscomb, PhD, Albert Pratt Public Service Professor at Harvard University’s John F. Kennedy School of Government, co-chair the committee. About 150 outside experts and consultants are contributing to the effort, which is expected to inform the decision-making process for the fiscal year 2004 budget.
In addition to his NAS commitment, Dr. Klausner continues to pursue research part time at NCI. He resigned as director last fall after more than 6 years in the post. He originally left to head a new institute established by the Case Foundation of AOL founder Steven Case and his wife, but the Cases withdrew their commitment to the project.
Articles in this issue
over 23 years ago
Bush to Complete 5-Year Doubling of NIH Budgetover 23 years ago
CAD Accurate in Digital Imagesover 23 years ago
Campath-1H Safe and Effective in Refractory B-CLLover 23 years ago
Involved-Field RT Is Effective in Hodgkin’s Diseaseover 23 years ago
FDA Approves Orfadin for Hereditary Tyrosinemia Type 1over 23 years ago
Allovectin-7 Immunotherapy Active in Metastatic Melanomaover 23 years ago
HAART Ups Survival in Primary CNS Lymphoma Patientsover 23 years ago
DX-8951f/Gemcitabine Safe, Active in Advanced Solid Tumorsover 23 years ago
Pseudomonas aeruginosa Infections After Transplant Rare But Deadlyover 23 years ago
ODAC Recommends That FDA Approve Zometa for Bone MetastasesNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.



















































































